Statistics from Altmetric.com
Assisted reproductive technology (ART) is a complex and expensive field of medicine. As such, new technology and new procedures are continually being developed with the aim of improving success rates. In the majority of cases, these are brought into clinical practice without sufficient research and development or scrutiny via randomised controlled trials (RCTs).1 Efficacy and safety issues should be considered before clinical application, including long-term follow-up of children.2 ,3
The issue with performing high-quality RCTs is that they are expensive to run and take several …
Competing interests DRB is a minor shareholder in Novocellus Ltd, a University of York spin-off company developing methods for diagnosing embryo health.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.